Improve the prevention of sudden cardiac arrest in emerging countries: the Improve SCA clinical study design

Shu Zhang, Balbir Singh, Diego A Rodriguez, Alexandr Robertovich Chasnoits, Azlan Hussin, Chi-Keong Ching, Dejia Huang, Yen-Bin Liu, Jeffrey Cerkvenik, Sarah Willey, Young-Hoon Kim, Shu Zhang, Balbir Singh, Diego A Rodriguez, Alexandr Robertovich Chasnoits, Azlan Hussin, Chi-Keong Ching, Dejia Huang, Yen-Bin Liu, Jeffrey Cerkvenik, Sarah Willey, Young-Hoon Kim

Abstract

Aims: This study aims to demonstrate that primary prevention (PP) patients with one or more additional risk factors are at a similar risk of life-threatening ventricular arrhythmias when compared with secondary prevention (SP) patients, and would receive similar benefit from an implantable cardioverter defibrillator (ICD), or cardiac resynchronization therapy-defibrillator (CRT-D) implant. The study evaluates the benefits of therapy for high-risk patients in countries where defibrillation therapy for PP of SCA is underutilized.

Methods: Enrolment will consist of 4800 ICD-eligible patients from Asia, Latin America, Eastern Europe, the Middle East, and Africa. Upon enrolment, patients will be categorized as SP or PP. Primary prevention patients will be assessed for additional risk factors: syncope/pre-syncope, non-sustained ventricular tachycardia, frequent premature ventricular contractions, and low left ventricular ejection fraction. Those PP patients with one or more risk factors will be categorized as '1.5' patients. Implant of an ICD/CRT-D will be left to the patient and/or physician's discretion. The primary endpoint will compare the appropriate ICD therapy rate between SP and 1.5 patients. The secondary endpoint compares mortality between 1.5 implanted and non-implanted patients.

Conclusion: The Improve SCA study will investigate a subset of PP patients, believed to be at similar risk of life-threatening ventricular arrhythmias as SP patients. Results may help clinicians identify and refer the highest risk PP patients for ICDs, help local societies expand guidelines to include PP of SCA utilizing ICDs, and provide additional geographical-relevant evidence to allow patients to make an informed decision whether to receive an ICD.

Trial registration: NCT02099721.

Keywords: LVEF; NSVT; PVCs; Primary prevention; SCA; Secondary prevention; Syncope.

© The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology.

Figures

Figure 1
Figure 1
Time to first appropriate VT/VF therapy in the OMNI clinical study. The panel on the left compares time with first treated VT/VF episode between PP and SP patients, and the panel on the right shows the results of the Improve SCA primary objective, comparing 1.5 prevention with SP. The P-values are from log-rank tests where a low P-value indicates a difference in the two curves.
Figure 2
Figure 2
Study flow chart.

References

    1. de Vreede-Swagemakers JJM, Gorgels APM, Dubois-Arbouw WI, van Ree JW, Daemen MJAP, Houben LGE, et al. Out-of-hospital cardiac arrest in the 1990s: A population-based study in the Maastricht area on incidence, characteristics, and survival. J Am Coll Cardiol 1997;30:1500–5.
    1. Rao BH. Global burden of sudden cardiac death and insights from India. Indian Heart J 2014;66:S18–23.
    1. Hua W, Zhang LF, Wu YF, Liu XQ, Guo DS, Zhou HL, et al. Incidence of sudden cardiac death in China: analysis of 4 regional populations. J Am Coll Cardiol 2009;54:1110–8.
    1. Rao BH, Sastry BKS, Chugh SS, Kalavakolanu S, Christopher J, Shangula D, et al. Contribution of sudden cardiac death to total mortality in India—a population based study. Int J Cardiol 2012;154:163–7.
    1. The APHRS White Book 2013. (23 April 2014, date last accessed).
    1. Gonzalez-Zuelgaray J, Pellizon O, Muratore CA, Oropeza ES, Rabinovich R, Ramos JL, et al. Lack of current implantable cardioverter defibrillator guidelines application for primary prevention of sudden cardiac death in Latin American patients with heart failure: a cross-sectional study. Europace 2013;15:236–42.
    1. Hua W, Niu H, Fan X, Ding L, Xu YZ, Wang J, et al. Preventative effectiveness of implantable cardioverter defibrillator in reducing sudden cardiac death in the Chinese population: a multicenter trial of ICD therapy versus non-ICD therapy. J Cardiovasc Electrophysiol 2012;23:S5–9.
    1. Olshansky B, Poole JE, Johnson G, Anderson J, Hellkamp AS, Packer D, et al. Syncope predicts the outcome of cardiomyopathy patients. Analysis of the SCD-HeFT Study. J Am Coll Cardiol 2008;51:1277–82.
    1. Sánchez JM, Katsiyiannis WT, Gage BF, Chen J, Faddis MN, Gleva MJ, et al. Implantable cardioverter-defibrillator therapy improves long-term survival in patients with unexplained syncope, cardiomyopathy, and a negative electrophysiologic study. Heart Rhythm 2005;2:267–373.
    1. Soteriades ES, Evans JC, Larson MG, Chen MH, Chen L, Benjamin EJ, et al. Incidence and prognosis of syncope. N Engl J Med 2002;347:878–85.
    1. Numeroso F, Mossini G, Lippi G, Cervellin G. Evaluation of the current prognostic role of heart diseases in the history of patients with syncope. Europace 2014;16:1379–83.
    1. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM, III, Freedman RA, Gettes LS, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2013;61:e6–75. Available online at: .
    1. Yap YG, Duong T, Bland JM, Malik B, Torp-Pederson C, Køber L, et al. Optimising the dichotomy limit for left ventricular ejection fraction in selecting patients for defibrillator therapy after myocardial infarction. Heart 2007;93:832–6. (Epub 19 January 2007).
    1. de Sousa MR, Morillo CA, Rabelo FT, Filho AMN, Ribeiro ALPALP. Non-sustained ventricular tachycardia as a predictor of sudden cardiac death in patients with left ventricular dysfunction: a meta-analysis. Eur J Heart Fail 2008;10:1007–14.
    1. Chen J, Johnson G, Hellkamp AS, Anderson J, Mark DB, Lee KL, et al. Rapid rate non-sustained ventricular tachycardia found on ICD interrogation: relationship of NSVT to outcomes in the SCD-HeFT trial. J Am Coll Cardiol 2013. .
    1. Anthony R, Daubert JP, Zareba W, Andrews ML, McNitt S, Levine E, et al. Mechanisms of VF Initiation in MADIT II Patients with ICDs. PACE, 2008;31:4–10.
    1. Taylor E, Berger R, Hummel J, Dinerman JL, Kenknight B, Arria AM, et al. Analysis of the pattern of initiation of sustained ventricular arrhythmias in patients with implantable defibrillators. J Cardiovasc Electrophysiol 2000;11:719–26.
    1. Roelke M, Garan H, McGovern B, Ruskin JN. Analysis of the initiation of spontaneous monomorphic ventricular tachycardia by stored intracardiac electrograms. J Am Coll Cardiol 1994;23:117–22.
    1. Perkiömäki JS, Bloch Thomsen PE, Kiviniemi AM, Messier MD, Huikuri HV; CARISMA study investigators Risk factors of self-terminating and perpetuating ventricular tachyarrhythmias in post-infarction patients with moderately depressed left ventricular function, a CARISMA sub-analysis. Europace 2011;13:1604–11.
    1. Bigger JT. Relation between left ventricular dysfunction and ventricular arrhythmias after myocardial infarction. Am J Cardiol 1986;57:8B.
    1. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM, III, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). Circulation 2008;117:2820–40.
    1. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace 2006;8:746–837.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner